The First Drug That Edits Your DNA Is Finally Selling
Casgevy revenue grew 78% in a single quarter and the FDA just opened the label to two-year-olds. The first CRISPR medicine is finally a business — and the market is still pricing its maker like a science project.
In December 2023, regulators in the United States and Europe approved something medicine had never seen: a therapy that treats disease by rewriting a patient's own DNA. Casgevy — built on the CRISPR/Cas9 editing system that earned its inventors a Nobel Prize — offers a one-time, potentially curative treatment for the two most common inherited blood disorders, sickle cell disease and beta thalassemia.
Then almost nobody bought it.
For two years, Casgevy was the most scientifically important drug in the world and one of the slowest launches in modern pharma. As late as the first quarter of this year, quarterly revenue was still running around $43 million — a rounding error for Vertex Pharmaceuticals, which commercializes the therapy, and a source of quiet embarrassment for CRISPR Therapeutics, the gene-editing pioneer that co-developed it and owns 40% of the economics.
That just changed. In the second quarter of 2026, Casgevy generated $76 million — up 78% in a single quarter and 151% year over year. The FDA extended the label to children as young as two, clearing the review in just 53 days and making roughly 5,500 additional US patients eligible overnight. The therapy is now approved in 39 countries, and in May, Germany — Europe's largest pharma market — agreed to reimburse it. Vertex now guides to roughly $500 million in combined 2026 revenue for Casgevy and its new pain drug, a 185% jump over last year.
Why the Launch Was Slow — and Why That Was Always the Plan
Casgevy was never going to launch like a pill. The treatment process explains everything about the revenue curve.
A patient's blood stem cells are harvested and shipped to a manufacturing site, where CRISPR/Cas9 edits the BCL11A gene switch — reactivating the fetal hemoglobin the body stopped producing in infancy. Before the edited cells go back in, the patient undergoes busulfan chemotherapy to clear out the old bone marrow, then spends weeks in the hospital while the new cells engraft. End to end, the journey takes months, and it can only happen at a qualified treatment center with cell-therapy infrastructure.
So for two years, Vertex wasn't really selling a drug. It was building a network: activating treatment centers across three continents, training transplant teams, and negotiating with insurers over how to pay $2.2 million once for a disease that otherwise costs millions of dollars per patient over a lifetime — much of it in emergency admissions for the agonizing pain crises that define severe sickle cell disease.
That is infrastructure spending, and infrastructure spending has a signature: a long flat line, then an inflection. The flat line is over. Patient cell collections — the leading indicator of future revenue, since each collection is a committed patient months from infusion — have been compounding for four straight quarters.
The Company Behind the Cure
Here is where it gets interesting for investors. Vertex is a $130-billion-class pharma giant; Casgevy's success moves its needle only modestly. CRISPR Therapeutics (NASDAQ: CRSP) is a different story. It holds 40% of Casgevy's economics, a $2.36 billion cash pile, and the most advanced wholly-owned pipeline in gene editing — and after a three-year bear market in biotech, the stock trades near $57, well below its 52-week high of $78 and roughly 80% below its 2021 peak.
Casgevy proves gene editing works as a commercial medicine. But sickle cell was never the prize — it was the proof. The therapy that cures 60,000 eligible patients is the demonstration project for a technology aimed at conditions measured in tens of millions: cholesterol, blood pressure, and the biggest killers in the developed world. In August, at the European Society of Cardiology Congress, CRISPR Therapeutics showed one-year data suggesting that pivot is already underway.
The question that matters for the stock: what is the market actually paying for that pipeline today? The answer, once you net out the cash, is surprisingly close to nothing — and that math is where we go next.
Get the next briefing free in your inbox: Join AlphaBriefing
The rest of this briefing is for paid members: the Casgevy revenue math and what CRSP's 40% share is realistically worth, the one-year CTX310 durability data that turns cholesterol into a one-shot edit, the enterprise-value calculation showing what the market pays for the entire pipeline, the three catalysts landing before year-end, and the bottom-line positioning framework.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.